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Hepatocellular carcinoma (HCC) is the third most common cause of cancer mortality. Short-term prognosis of patients with
HCC has improved recently due to advances in early diagnosis and treatment, but long-term prognosis is still unsatisfactory.
Therefore, obtaining a further understanding of the molecular carcinogenic mechanisms and the unique pathogenic biology of
HCC is important. The most characteristic process in hepatocarcinogenesis is underlying chronic liver injury, which leads to
repeated cycles of hepatocyte death, inﬂammation, and compensatory proliferation and subsequently provides a mitogenic and
mutagenic environment leading to the development of HCC. Recent in vivo studies have shown that the stress-activated mitogen-
activated protein kinase (MAPK) cascade converging on c-Jun NH2-terminal kinase (JNK) and p38 plays a central role in these
processes, and it has attracted considerable attention as a therapeutic target. However, JNK and p38 have complex functions and
a wide range of cellular eﬀects. In addition, crosstalk with each other and the nuclear factor-kappaB pathway further complicate
these functions. A full understanding is essential to bring these observations into clinical settings. In this paper, we discuss the
latest ﬁndings regarding the mechanisms of liver injury and hepatocarcinogenesis focusing on the role of the stress-activated
MAPK pathway.
1.Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common
cancer and the third most common cause of cancer mortality
worldwide [1]. The age-adjusted incidence rate of HCC
varies geographically, with high rates in East Asia and mod-
erate rates in Europe, North/South America, and Oceania. In
addition, a deﬁnite increase in HCC incidence has recently
been reported in Europe and North America [2].
Although the etiology of background liver disease varies
geographically, chronic hepatitis B virus (HBV) or hepatitis
C virus (HCV) infection is the main cause of HCC in most
areas. Other major etiologies include alcoholic hepatitis,
hemochromatosis, and nonalcoholic steatohepatitis (NASH)
[1, 3]. Accumulating evidence indicates that a sustained
inﬂammatory reaction in the liver is the major contributing
factor to the development of HCC. For example, in chronic
hepatitisC,thehostimmuneresponsestoHCVareoftennot
strong enough to completely clear the infection, resulting in
chronic stimulation of an antigen-speciﬁc immune response
[4]. Hepatocyte damage is induced by the continued expres-
sion of cytokines and recruitment of activated inﬂamma-
tory cells to the liver, which is followed by hepatocyte
regeneration.Thispersistentcycleofnecroinﬂammationand
hepatocyte regeneration is thought to provide a mitogenic
and mutagenic environment leading to the development of
HCC [5–7].
Eﬀective treatments for HCC include surgical resection,
percutaneous ablation, and liver transplantation. Although
liver transplantation results in a better survival rate [8],
its application is limited by the scarcity of donor organs.
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a high rate of complete responses [9, 10], but long-term
prognosis is not satisfactory, as indicated by the low overall
survival of 22%–35% at 10 years [2]. This is due to frequent
recurrenceandlackofeﬀectivetreatmentforadvancedHCC.
Transarterialchemoembolization,radiotherapy,andconven-
tional chemotherapy have been performed for advanced
HCC, but their eﬃcacies are limited [11].
Recently, molecular-targeted therapy was developed for
the treatment of HCC. Sorafenib is a small molecule multi-
kinase inhibitor targeting the Raf serine/threonine kinases,
vascular endothelial growth factor receptor (VEGFR) and
platelet-derived growth factor receptor (PDGFR) pathway.
In the SHARP (Sorafenib HCC Assessment Randomized
Protocol) trial, sorafenib signiﬁcantly prolonged median
overallsurvivalcomparedtoplacebo(10.7versus7.9months,
resp.) [12]. However, median survival was not satisfactory
even in the sorafenib group. Although other molecular-
targeting agents are currently under investigation, only
limited improvements in survival beneﬁt have been reported
[13].
Eradicationofthecauseofchronicinﬂammation,suchas
hepatitis viruses, is the most beneﬁcial means of preventing
HCC [14]. Recent advances in antiviral treatment have made
the eradication of HCV or signiﬁcant suppression of HBV
replication possible [15–17]. However, these therapies are
not eﬀective for all patients, and the development of HCC
will not be prevented completely, especially in patients with
advanced ﬁbrosis. In addition, in patients with HCC based
on metabolic syndrome including NASH, the incidence rate
of which is increasing, dietary modiﬁcations and exercise are
fundamental, but these approaches are sometimes ineﬀective
andgeneticbackgroundmayalsobeimportantinsuchcases.
Furthermore, once HCC has developed, the recurrence rate
doesnotdeclinewithtimeregardlessofbackgroundliverdis-
ease, suggesting that most cases of late-phase recurrence are
duetometachronousmulticentriccarcinogenesis[11].Thus,
gaining further understanding of the molecular mechanisms
of carcinogenesis in HCC is important to discover new
moleculartargets,especiallyforpreventingtheoccurrenceor
recurrence of HCC and systemic therapy for patients in the
advanced stage.
Several molecular pathways have been reported to play
important roles in hepatocarcinogenesis. As mentioned
above, inﬂammation-mediated liver injury and compen-
satory hepatocyte proliferation are indispensable compo-
nents during HCC development. Recent high-quality in vivo
studies have shown that stress-activated mitogen-activated
protein kinase (MAPK) signaling converging on c-Jun NH2-
terminal kinase (JNK) and p38 plays a central role in
these processes, and it has attracted considerable attention
as a therapeutic target [18–24]. In this paper, we discuss
the mechanisms of liver injury and hepatocarcinogenesis
focusing on the role of the stress-activated MAPK pathway.
2. GeneralRole of JNK in the Liver
2.1. Stress-Activated MAPK. MAPK cascades are signaling
systems that transmit stimuli from outside the cell to the
nucleus [25, 26]. Three major MAPK cascades have been
characterized in detail, converging on ERKs, JNKs, and p38
MAPKs; each consists of three classes of serine/threonine
kinases, MAPK, MAPK kinase (MAPKK), and MPKK kinase
(MAP3K). MAP3K phosphorylates and thereby activates
MAPKK, and activated MAPKK in turn phosphorylates and
activates MAPK (Figure 1). Among the three MAPKs, ERKs
are activated by various cytokines and growth factors and
play a central role in cell growth and diﬀerentiation. JNKs
and p38 MAPKs, also called stress-activated MAPKs, are
preferentially activated by proinﬂammatory cytokines, such
as tumor necrosis factor α (TNFα) and environmental and
genotoxic stresses. After activation, stress-activated MAPKs
phosphorylate speciﬁc serine/threonine residues of target
substratesandexertavarietyofcellularfunctions,suchascell
death, survival, proliferation, migration, and inﬂammation.
2.2. JNK Signaling. JNK has three isoforms (JNK1, JNK2,
and JNK3) encoded by three diﬀerent genes. JNK1 and
JNK2 are expressed in almost all organs, including the liver,
whereas JNK3 is a neuronal-speciﬁc isoform [27]. JNK is
phosphorylated and activated by two MAPKKs, MKK4, and
MKK7. Activated JNK phosphorylates and thereby activates
c-Jun, JunD, ATF, and other transcription factors, which are
involvedintheformationandactivationoftheAP-1complex
[28]. In addition, JNK also modulates the function of other
proteins by phosphorylation, such as Bcl-2 family members,
which are closely related to apoptotic cell death factors
[29]. Furthermore, although JNK1 and JNK2 isoforms
play redundant roles in many physiological processes, they
also have distinct biological activities in some situations
[30]. For example, JNK1-deﬁcient CD8+ T cells are unable
to undergo antigen-stimulated expansion, whereas JNK2-
deﬁcient CD8+ T cells are hyperproliferative [31]. Therefore,
the role of JNK in controlling diverse cellular functions,
such as cell proliferation, diﬀerentiation, and apoptosis, is
basedonthephosphorylationandfunctionalmodiﬁcationof
downstream molecular targets in a stimulus- and cell-type-
dependent manner.
2.3. Role of JNK in TNFα-Mediated Liver Injury. Underlying
liver injury, which leads to repeated cycles of hepatocyte
death, inﬂammation, and compensatory proliferation, is an
indispensable factor in the development of most liver can-
cers. Therefore, determining the mechanism of liver injury is
abasicrequirementforunderstandinghepatocarcinogenesis.
The proinﬂammatory cytokine TNFα plays a pivotal
role in various inﬂammatory liver diseases [32]. Serum and
hepatic TNFα levels are increased in patients with acute
and chronic viral hepatitis, alcoholic hepatitis, and NASH
[33–36]. Although TNFα can kill hepatocytes during such
liver diseases, the healthy liver usually has defense systems
against TNFα-induced cell death. In fact, TNFα stimulates
proliferationratherthandeaththroughDNAsynthesisinthe
normal hepatocyte, which is required for liver regeneration
after partial hepatectomy [37, 38]. However, once antiapop-
totic response is inhibited, TNFα signaling is converted from
proliferation to apoptosis. Thus, TNFα has the capacity toPathology Research International 3
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Figure 1: Stress-activated MAPK signaling pathway. This pathway
consists of three classes of protein kinase—MAP3K, MAPKK, and
MAPK—and converges on JNK and p38 through a kinase cascade.
Only representative molecules are shown in MAP3K.
induce hepatocyte death as well as hepatocyte proliferation,
and plays a crucial role in preserving liver homeostasis [39].
Recent studies have uncovered the important role of the
cross talk between JNK and nuclear factor-kappaB (NF-κB)
pathways in these processes, as described later.
TNFα is produced mainly by Kupﬀer cells in the liver and
exerts biological eﬀects by binding to two plasma membrane
receptors, TNF-receptor 1 (TNF-R1) and TNF-R2 [40]. The
majority of the biological eﬀects of TNFα are mediated by
TNF-R1. Upon binding of TNFα to TNF-R1, the signaling
molecule TNF-R-associated death domain (TRADD), TNF-
R-associated factor 2 (TRAF2), and receptor interacting
protein 1 (RIP1) are recruited to form the so-called complex
I[ 41]( Figure 2). Assembly of this complex is essential to
activate two key players, JNK and NF-κBp a t h w a y s .
In addition to the formation of complex I, TNFα
binding to TNF-R1 simultaneously recruits Fas-associated
death domain (FADD) and caspase-8, thus forming another
complex, the so-called complex II [41]( Figure 2). Here,
caspase-8 is activated through autocatalytic cleavage and
active caspase-8 is then able to proteolytically activate several
eﬀector caspases such as caspase-3. However, in the case of
hepatocytes, the amount of active caspase-8 generated by
complex II is too small for activation of eﬀector caspases,
requiring an ampliﬁcation loop through mitochondria [42].
Caspase-8 cleaves Bid to a truncated form, tBid, which
translocates to the mitochondria, causing activation of
Bak/Bax and subsequent activation of the mitochondrial
apoptotic pathway. This mitochondrial pathway involves the
release of numerous apoptogenic factors from the mito-
chondrial intermembrane space into the cytosol, including
cytochrome c,w h i c ha c t i v a t e se ﬀector caspases and then
induces cell death and ampliﬁcation of caspase-8 activation.
The importance of JNK in TNFα-mediated liver injury
has been conﬁrmed by many in vitro and in vivo studies.
In an in vitro study, TNFα-induced apoptosis was blocked
by the small molecule JNK inhibitor SP600125 in mouse
and rat primary hepatocytes [43]. In vivo,N F - κB-deﬁcient
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Figure 2: Signaling pathways of TNFα-induced hepatocyte death.
After binding of TNFα to TNF-R1, complexes I and II are formed.
As the amount of caspase-8 activation in complex II is not suﬃcient
to induce cell death of hepatocytes, activation of the mitochondrial
apoptotic pathway is essential. Activated caspase-8 initiates the
mitochondrial apoptotic pathway by cleaving Bid to tBid. In addi-
tion, JNK can also activate the mitochondrial apoptotic pathway
though modulation of Bcl-2 family members or degradation of c-
FLIP. These pathways cooperate to induce cell death, while NF-κB
and p38 inhibit TNFα-induced hepatocyte death by suppressing
JNK activation through various mechanisms.
embryos, which normally die due to TNFα-mediated hep-
atocyte apoptosis, were shown to survive longer when the
JNK1 gene was also disrupted [44]. In addition, JNK1
knockout (JNK1−/−) and JNK2 knockout (JNK2−/−)m i c e
were resistant to concanavalin-A-(Con-A-) induced liver
injury, which is primarily TNFα dependent [45]. In another
study, JNK2−/− mice, but not JNK1−/−, mice were shown
to be resistant to lipopolysaccharide (LPS)/d-galactosamine
(GalN)-inducedliverinjury,whichisalsoaTNFα-dependent
liver injury model [46]. A recent study showed that both
JNK1−/−,a n dJNK2−/−, mice are resistant to LPS/GalN-
induced liver injury, and JNK2 plays a more prominent
role in TNFα-induced hepatocyte death [47]. Despite the
discrepancies among studies concerning which of the JNK
isoforms is more important in hepatocyte death, they all
support the concept that JNK plays a key role in controlling
TNFα signaling toward cell death.
As TNFα-mediated hepatocyte death is also important
for acute liver injury, JNK is considered to be a promising
therapeutictargetforacuteliverinjury.Infact,SP600125and
another JNK inhibitor D-JNKi, which is a peptide inhibitor
of JNK, exert protective eﬀects on LPS/GalN-induced fulmi-
nant hepatitis [44, 48].4 Pathology Research International
2.4. Reactive Oxygen Species as Upstream Activators of JNK
in TNFα Signaling. TNFα binding to TNF-R1 leads to the
formation of complex I and then activates a member of
the MAP3K family, transforming growth factor β-activated
kinase 1 (TAK1). Activated TAK1 activates MKK4 and
MKK7, which leads to JNK activation [49]. However, tran-
sient activation of JNK is not suﬃcient to induce cell death.
Reactive-oxygen-species-(ROS-) mediated prolongation of
JNK activation is considered important for the proapoptotic
function of JNK. This concept was supported by the higher
levels of intracellular ROS observed in TNFα-treated cells
and the observation that antioxidants, such as N-acetyl-l-
cysteine which is precursor of glutathione and butylated
hydroxyanisole which is synthetic antioxidant authorized as
a food additive, can suppress TNFα-induced prolonged JNK
activation and subsequent apoptosis [30].
In TNFα signaling, two mechanisms have been pro-
posed for ROS-mediated prolongation of JNK activation.
One study indicated that ROS extended JNK activation by
inactivating MAPK phosphatases (MKPs), which are essen-
tial for dephosphorylation of activated JNK [50]. TNFα-
induced ROS oxidize critical Cys residues in the catalytic
sites of various MKPs, leading to their inactivation, and
ROS-mediated oxidation of MKP-1 rapidly leads to its
degradation by the ubiquitin-proteasome pathway. Another
study demonstrated an important role of apoptosis signal-
regulating kinase 1 (ASK1), one of the major MAP3Ks, in
theregulationofstress-activatedMAPK[51].TNFα-induced
sustained activation of JNK is lost in ASK1−/− embryonic
ﬁbroblasts, and ASK1−/− cells are resistant to TNFα-induced
apoptosis. While TAK1 is activated directly by TNF-R1-
induced signaling, activation of ASK1 is secondary to the
generation of ROS. The involvement of ASK1 in ROS-
mediatedJNKactivationisbasedonlinksbetweenASK1and
thioredoxin (Trx), a reduction/oxidation regulatory protein
[52]. In the absence of oxidative stress, Trx inhibits ASK1
kinase activity via direct binding to the N-terminal region
of ASK1. Excess oxidative stress converts Trx to its oxidized
form,resultinginitsdissociation fromASK1andsubsequent
ASK1 kinase activation. This system has been conﬁrmed to
functionintheliverinvivousinganacetaminophen-induced
liver injury model, which is a typical ROS-mediated liver
injury model [53]. In addition, a recent study showed that
ASK1−/− miceareresistanttoLPS/GalN-inducedliverinjury
[54]. Furthermore, Trx transgenic mice are also resistant to
LPS/GalN-induced liver injury [55]. Thus, TNFα-induced
ROS prolongs JNK activity by blocking the inhibitory MKPs
and simultaneously promoting the activation of ASK1, then
shifting the balance from cell survival toward cell death.
Viral proteins, including HCV core proteins, are also
capable of ROS accumulation in hepatocytes, and ROS-
mediated JNK activation in the liver is linked not only to
liver disease but also to systemic disorders, such as insulin
resistance and metabolic syndrome. Therefore, further eluci-
dation of this process is very important [56–58].
2.5. Downstream Targets of JNK in TNFα-Induced Cell Death.
Several targets of JNK in TNFα-induced cell death have
been proposed. The primary question is whether JNK is or
is not involved in caspase-8 activation. JNK was initially
suggested to induce caspase-8-independent cleavage of Bid
at a site distinct from the Bid cleavage product jBid, which
translocates to mitochondria and subsequently ampliﬁes
caspase-8 activation [59]. However, this ﬁnding has not been
conﬁrmed in an in vivo liver injury model. In the LPS/GalN-
induced liver injury model, JNK2−/− mice showed signiﬁ-
cant attenuation of caspase-8 activation and subsequent Bid
cleavage, suggesting that JNK2 acts at the level of caspase-8
activation [46]. However, the detailed mechanism remains
unclear and attenuated caspase-8 activation may be the
indirect resultofa lackofampliﬁcation bythemitochondrial
release of proapoptotic factors. JNK may also be involved
in caspase-8 activation through regulation of the caspase-8
inhibitor c-FLIPL [44] .P r o l o n g e da c t i v a t i o no fJ N K 1l e a d s
to phosphorylation of Itch, thereby activating its ubiquitin
ligase activity, which results in polyubiquitination and sub-
sequent degradation of c-FLIPL. As c-FLIPL competes with
caspase-8 for binding to complex II and impairs caspase-
8 activation, JNK1-mediated c-FLIPL degradation results in
full activation of caspase-8 and cell death. These studies
support the suggestion that JNK is located upstream of
caspase-8 activation.
OtherstudiessupportthealternativesuggestionthatJNK
plays an apoptotic role at a level farther downstream through
the regulation of Bcl-2 family activation. Activated JNK
has been shown to phosphorylate and inactivate the anti-
apoptotic proteins Bcl-2 and Bcl-xL [60–62]. Furthermore,
activated JNK promotes Bax translocation to mitochondria
through phosphorylation of 14-3-3, a cytoplasmic anchor of
Bax. Phosphorylation of 14-3-3 leads to dissociation of Bax
from this protein [63]. A more recent study showed that JNK
contributes to TNFα-induced cell death through phospho-
rylation of the pro-apoptotic BH-3-only protein Bim, rather
than Bid [64]. JNK-mediated Bim phosphorylation triggers
the proapoptotic activity of Bim by causing its release from
sequestration to the microtubular dynein motor complex
and then activates the mitochondrial apoptotic pathway [65,
66]. These studies indicated that JNK acts in parallel and
independent of caspase-8. Thus, although the downstream
targets of JNK in TNFα signaling are not fully understood,
most studies have demonstrated that JNK is required for
activation of the mitochondrial apoptotic pathway.
2.6. Crosstalk between JNK and NF-κB. As prolonged JNK
activationiscloselyrelatedtocelldeath,systemsfortheregu-
lation of JNK activity are mandatory for tissue homeostasis.
The crosstalk between NF-κB and JNK is considered to be
a major determinant in the fate of hepatocytes, including
TNFα signaling.
NF-κB is a transcription factor that consists of homod-
imers and heterodimers composed of ﬁve members, that
is, p65 (RelA), c-Rel, RelB, p50, and p52 [67]. Each NF-
κB dimer has a diﬀerent DNA-binding aﬃnity and controls
speciﬁc targets. Additionally, transcriptional activity of NF-
κB is regulated by transcription coactivators such as SRC
family and corepressors such as HDAC family [68]. The
p50/p65 heterodimer, the most abundant form of the NF-
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stimulation, this heterodimer is bound to speciﬁc inhibitory
factors, such as inhibitor of NF-κB( I κB) proteins in the
cytoplasm. TNFα signaling complex I activates canonical
NF-κB pathway via the IKK complex, which consists of
two catalytic subunits, IKKα and IKKβ, and a regulatory
component, IKKγ/NEMO (Figure 2). The IKK complex
phosphorylates and subsequently induces degradation of
IκB. Once activated, NF-κB dimers translocate into the
nucleus and stimulate transcription of various genes, such as
those encoding cytokines and antiapoptotic factors.
Hepatocyte-speciﬁc IKKβ or NEMO knockout mice are
more sensitive to the hepatotoxic eﬀects of injecting Con-
A or LPS, respectively, suggesting a crucial role of NF-κB
activation in protection from TNFα-induced liver injury
[45, 69]. Also note that the extent of TNFα-induced JNK
activation is strengthened and prolonged in these mice.
SeveralmechanismshavebeenproposedbywhichNF-κB
activation controls the level of JNK activation. At least three
NF-κB-dependent genes have been identiﬁed as potential
candidates, that is, growth arrest DNA damage-inducible
gene45β(Gadd45β),X-linkedinhibitorofapoptosis(XIAP),
and the zinc ﬁnger protein A20 [70–76]. However, the
precise implications and detailed mechanisms of action of
these molecules in the regulation of TNFα-induced JNK
activation and cell death remain unclear, especially in vivo.
In addition to the expression of JNK inhibitory proteins, NF-
κB also inhibits JNK activation by controlling intracellular
ROS levels. NF-κB activation leads to expression of the
antioxidants ferritin heavy chain (FHC) and manganese-
dependent superoxide dismutase (MnSOD), both of which
prevent accumulation of ROS, thus inhibiting prolongation
of JNK activation [77, 78].
2.7. Crosstalk between JNK and Other MAPK Signaling Mol-
ecules. p38α also plays an important role in inhibiting
TNFα-induced JNK activation and liver injury. Hepatocyte-
speciﬁc p38α knockout mice showed much stronger JNK
activation after administration of LPS [79]. Although p38α
ablation is not suﬃc i e n tt oi n d u c eh e p a t o c y t ed e a t ha f t e r
LPS administration, hepatocyte-speciﬁc p38α,a n dI K K β
double-knockout mice show severe liver injury, suggesting
that p38α and IKKβ act synergistically to protect the
liver from TNFα-induced toxicity. Unlike in the case of
NF-κB, pretreatment with antioxidants could not reduce
LPS-induced JNK activation in hepatocyte-speciﬁc p38α
knockoutmice.Furthermore,thelevelsofMKPsweresimilar
between hepatocyte-speciﬁc p38α knockout mice and wild-
type controls. Therefore, the detailed mechanisms of action
of p38α in regulating TNFα-induced JNK activation and
cell death remain unclear. However, hepatocyte-speciﬁc
p38α knockout mice showed increased MKK4 activation, so
targets of p38α are considered to be upstream of JNK, such
as MAPKKs and MAP3Ks. Interestingly, not only MKK4 but
also MKK3 and MKK6 activation, all of which are involved
in p38 activation, are increased in hepatocyte-speciﬁc p38α
knockout mice, suggesting that there might be negative
feedback mechanism in p38 signaling pathway in the liver. In
fact, p38 has been reported to negatively regulate upstream
MAP3Ks such as TAK1 and MLK3 in other cells [80, 81].
Two recent studies have introduced MAP3K TAK1 into
the complex ﬁeld of NF-κB/JNK interaction in the liver
[82,83].InTNFαsignaling,TAK1isrecruitedintocomplexI
and phosphorylated through TRAFs. Then, phosphorylated
TAK1 activates IKK and MKK4/7. Therefore, TAK1 can
activate both NF-κB and JNK, which play opposing roles
in cell death. Inokuchi et al. reported that hepatocyte-
speciﬁc TAK1 knockout mice generated by intercrossing
TAK1 ﬂoxed mice with Alb-Cre mice showed spontaneous
hepatocyte death, which was partially canceled by further
genetic deletion of TNF-R1, suggesting that TAK1-deﬁcient
hepatocytes are sensitive to endogenous TNFα [82]. They
also reported that hepatocyte-speciﬁc TAK1-deﬁcient mice
showed enhanced JNK activation in vivo. Primary hepato-
cytes derived from these mice also demonstrated enhanced
cell death by TNFα stimulation, and not only NF-κB
activation but also JNK activation were inhibited ex vivo.
Bettermann et al. reported that liver-speciﬁc TAK1 knockout
mice generated by intercrossing TAK1 ﬂoxed mice with
Alfp-Cre mice showed strong JNK activation, lack of NF-
κB activation, and massive hepatocyte apoptosis after LPS
injection [83]. This enhanced JNK activation may occur
through activation of other MAP3K TAO2. Furthermore,
they showed that TAK1 is required for the prevention of
cholangiocyte apoptosis. Thus, although the role of TAK1
in the regulation of TNFα-mediated JNK activation has not
beenfullyelucidated,TAK1playsanantiapoptotic roleinthe
liver mainly through NF-κB activation.
2.8. Implication of JNK in Other Types of Liver Injury. JNK
signaling has also been implicated in hepatocyte injury due
to other causes, including lipotoxicity, ER stress, ischemia-
reperfusion, and drug toxicity, such as from acetaminophen
[53, 84–87]. Although the role of JNK in these types of
hepatocyte death cannot be discussed here in detail due
to space limitations, JNK is generally considered to play
an important role in cell death induction through similar
mechanisms as seen in TNFα signaling. Therefore, JNK is a
possiblecandidatetherapeutictargetforvarioustypesofliver
injury.
3. JNK inHepatocarcinogenesis
3.1.GeneralFunctionofJNKinCarcinogenesis. Althoughthis
review has mainly discussed the pro-apoptotic function of
JNK, this molecule has various functions in carcinogenesis.
First, JNK plays an important role in cell proliferation. JNK
is considered to be involved in cell cycle progression mostly
through interaction with the transcription factor c-Jun,
which is a well-established cell cycle regulator. A previous
study using JNK1−/− or JNK2−/− ﬁbroblasts showed that
JNK2−/− ﬁbroblasts proliferate faster with increased c-Jun
expression, whereas JNK1−/− ﬁbroblasts proliferate slower
with decreased c-Jun expression, suggesting that JNK1 might
play a major role in c-Jun-mediated cell cycle progression
[88]. However, another study using ﬁbroblasts from mice
withaknockin mutationintheJNK2geneshowedthatJNK2
is also involved in c-jun expression and cellular proliferation6 Pathology Research International
[89]. Thus, in general, both JNK1 and JNK2 play important
roles in cell cycle progression.
In the liver, JNK1 has been shown to be a major player in
cell cycle regulation using a partial hepatectomy model. Hui
et al. reported that the number of Ki67-positive proliferating
hepatocytesinJNK1−/− micewassigniﬁcantlyreducedcom-
pared to wild-type controls after partial hepatectomy [20].
The impaired proliferation in JNK1−/− mice was caused
by increased expression of p21, a cell cycle inhibitor, and
reduced expression of c-Myc, a negative regulator of p21. In
contrast, JNK2−/− mice showed similar hepatocyte prolifer-
ation rates to wild-type controls. Another study showed that
administration of the pan-JNK inhibitor SP600125 inhibited
hepatocyte proliferation after partial hepatectomy through
reduced expression of cyclin D1 [90]. Thus, JNK plays an
important role in hepatocyte proliferation in vivo.
In addition to its roles in cell proliferation, JNK has been
shown to also have various oncogenic functions. For exam-
ple, the JNK pathway is involved in HCC cell migration and
tumor invasion through matrix metalloproteinase (MMP)
production [91]. A recent study showed that JNK is required
for Ras-induced suppression of contact growth inhibition
by regulating e-cadherin expression [92]. Furthermore, JNK
facilitates cancer progression by interacting with other
oncogenic pathways, such as Wnt/β-catenin signaling [93–
95]. Thus, although JNK is generally considered to play
oncogenic roles, it also plays roles in tumor suppression
in some cases through p53 activation and induction of
apoptosis [96–98].
3.2. Role of JNK in Hepatocarcinogenesis. In general, induc-
tion of cell death acts as a tumor-suppressing function.
H o w e v e r ,t h i sf u n c t i o nd o e sn o ta l w a y sa c ta sat u m o r
suppressor, but instead acts as a tumor promoter in the liver,
because the loss of hepatic mass due to hepatocyte death
activates the proliferation of residual hepatocytes that may
provide a promoting environment for tumor formation.
Recent in vivo studies strongly implicated JNK as a key
regulator in this process.
Diethylnitrosamine (DEN) is a chemical carcinogen
commonly used to induce HCC in rodents. Administration
of DEN causes acute liver injury and DNA damage in the
hepatocytes, and subsequently leads to inﬂammation, liver
regeneration, and neoplastic lesions in the liver. A study
using hepatocyte-speciﬁc IKKβ knockout mice demon-
strated a critical concept with regard to the role of cross talk
between NF-κB and JNK in hepatocytes in DEN-induced
HCC [78]( Figure 3). Hepatocyte-speciﬁc knockout of IKKβ
markedly enhanced DEN-induced HCC. The ablation of
hepatocyte IKKβ induces greater DEN-induced JNK activa-
tion and greater cell death during the acute reaction to DEN
administration. The absence of NF-κB induces prolonged
JNK activation by enhancing ROS production, and pro-
longed JNK activation plays a critical role in DEN-induced
hepatocyte death, as seen in TNFα-mediated liver injury.
Subsequently, the elevated hepatocyte death rate enhances
compensatory proliferation. Thus, the hepatocyte-speciﬁc
deletion of IKKβ augments DEN-induced hepatocyte death,
compensatory proliferation, and increased tumorigenesis,
probably through enhanced JNK activation. Similar ﬁndings
were obtained in mice lacking NEMO, the hepatocyte-
speciﬁc deletion of which results in spontaneous liver dam-
age, hepatosteatosis, ﬁbrosis, and the development of HCC
[69]. To further investigate the role of JNK in this process,
JNK1−/− mice were interbred with hepatocyte-speciﬁc IKKβ
knockout mice, and the double-knockout mice developed
signiﬁcantly fewer tumors compared to IKKβ knockout mice
[18]. In addition, JNK1−/− mice showed a signiﬁcant reduc-
tion of tumor development compared to wild-type controls.
In addition to the involvement in DEN-induced acute liver
injury, JNK1 has tumor-promoting functions by enhancing
cancer cell proliferation and neovascularization through the
increased expression of cyclin D1 and VEGF, respectively.
Another group also reported the critical role of JNK1 in
hepatocarcinogenesis using the DEN and phenobarbital-
induced HCC model [20]. They showed that cancer cell
proliferation decreases signiﬁcantly in JNK1−/− mice due
to increased p21 expression and reduced c-Myc expression.
In addition, pharmacological inhibition of JNK by D-JNKi
reduced the growth of xenografted human HCC cells and
chemically induced mouse liver cancers, suggesting that JNK
is a promising therapeutic target for HCC. Their study,
however, also showed that JNK2 is not involved in hep-
atocarcinogenesis. About 50%–60% of human HCC show
strong activation of JNK1 compared to adjacent nontumor
tissue, whereas JNK2 activation is similar between HCC and
non-tumor tissue [20, 99]. These results suggest that JNK,
especially JNK1, plays an important role in the development
of HCC.
JNK activation is also implicated in HCC based on
viral hepatitis. In vitro studies showed that several HBV
and HCV proteins can activate the JNK pathway [100,
101]. In addition, JNK-mediated enhanced cell proliferation
is involved in hepatocarcinogenesis of HCV core protein
transgenic mice and HBx protein transgenic mice, both of
which spontaneously develop HCC [102, 103].
However, a more recent study using conditional knock-
out mice of both JNK isoforms, JNK1 and JNK2, suggested
that JNK may play dual roles in hepatocarcinogenesis [104].
In their study, JNK deﬁciency in hepatocytes increased DEN-
induced HCC. In contrast, JNK deﬁciency in both hepato-
cytes and myeloid cells reduced hepatic inﬂammation and
thedevelopmentofHCC.Althoughthedetailedmechanisms
remain unclear, this study suggested that JNK in hepatocytes
may act as a tumor suppressor, whereas that in myeloid cells
may act as a tumor promoter in the development of HCC.
JNK is also wellknown as a critical regulator of obesity
and metabolic syndrome through inhibition of insulin
signaling in the liver and muscle, and modulation of adi-
pokine secretion from adipocytes [105, 106]. Recent stud-
ies have suggested that obesity-induced insulin resistance
and dysregulation of adipokines play important roles in
hepatocarcinogenesis [107–110]. As the incidence rate of
this metabolic syndrome-associated hepatocarcinogenesis is
likely to increase in the near future, investigating whether
JNK activation also contributes to hepatocarcinogenesis
under this condition is critical.Pathology Research International 7
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Figure 3: Current model of the role of stress-activated MAPK and NF-κB in inﬂammation-mediated hepatocarcinogenesis. In chronic liver
injury, hepatitis virus, ROS, toxins, and cytokines kill hepatocytes. JNK promotes cell death, while NF-κB and p38 promote cell survival.
Dying hepatocytes activate Kupﬀer cells via TLR or IL-1R. Activated Kupﬀer cells secrete cytokines, such as IL-6 and TNFα, through a
mechanism mediated by NF-κB and p38. Subsequently, these cytokines induce recruitment of activated inﬂammatory cells to the liver,
which is followed by hepatocyte regeneration. JNK and STAT3 promote cytokine-mediated hepatocyte proliferation. This persistent cycle of
necroinﬂammation and hepatocyte regeneration provides a mitogenic and mutagenic environment, leading to the development of HCC.
4. p38 and MAP3Ks inHepatocarcinogenesis
4.1. p38 Signaling. The p38 MAPK group consists of four
members: p38α,p 3 8 β,p 3 8 γ, and p38δ [111]. p38α and p38β
are universally expressed and closely related proteins that
have overlapping functions. Whereas p38α is highly abun-
dant in most cell types, p38β seems to be expressed at very
low levels. p38γ and p38δ have more restricted expression
patterns and are likely to have specialized functions [23].
Most of the published literature on p38 MAPKs refers to
p38α, and we mainly discuss p38α in this paper. MKK3
and MKK6 are the primary upstream MAPKKs of p38, but
MKK4 has also been shown to activate p38 in response to
certain stimuli. p38 can also be activated independently of
the MAP3K/MAPKK cascade by autophosphorylation [112].
Substrates of p38 include protein kinases, such as MAPKAP
kinase 2 (MK2) and MK5, and transcription factors, such
as ATF2, p53, and Mitf [113]. These diverse targets mediate
the activated p38 signal to various types of cellular functions
such as diﬀerentiation, apoptosis, cytokine production, and
cell cycle control.
4.2. General Function of p38 in Carcinogenesis. Although p38
was ﬁrst recognized as a regulator of inﬂammatory cytokine
production, recent studies uncovered a role of p38α as
an essential inhibitor of cell proliferation. p38α negatively
regulates cell cycle progression both at the G1/S and G2/M
transitions by several mechanisms, including the downreg-
ulation of cyclins, upregulation of cyclin-dependent kinase
(CDK) inhibitors, and modulation of the tumor suppressor
p53 [114]. p38α also acts as an inhibitor of hepatocyte
proliferation after partial hepatectomy, and inactivation of
p38α is seen during liver regeneration [115, 116]. This eﬀect
of p38α is partially mediated by negative regulation of the
JNK/c-Jun pathway [19].
In addition to the suppression of cell proliferation, p38
exerts tumor-suppressing eﬀects through oncogene-induced
senescence (OIS), contact inhibition, and DNA damage
responses [111]. In particular, recent studies demonstrated
a major role of p38 in OIS caused by oncogenic Ras or
its downstream eﬀector Raf-1. The Ras-Raf-MEK-ERK sig-
naling cascade increases the intracellular ROS level and
subsequently activates the p38 pathway [117]. Activated
p38 phosphorylates multiple residues on p53, leading to
increased transcriptional activity of p53 and induction of
p21 [111, 118]. Active p38 also induces the expression of
p16 and p14/p19, which together with the p53-p21 cascade,
cause senescence that serves as a tumor-suppressing defense
mechanism [119]. Thus, a great deal of evidence supports
ar o l eo fp 3 8a sat u m o rs u p p r e s s o r .H o w e v e r ,p 3 8m a y
also have oncogenic eﬀects by facilitating cell invasion,
inﬂammation, and angiogenesis [120, 121].
4.3. Role of p38 in Hepatocarcinogenesis. The role of p38 in
hepatocarcinogenesis has also been investigated using the
DEN-induced mouse HCC model. Similar to hepatocyte-
speciﬁc IKKβ knockout mice, hepatocyte-speciﬁc p38α8 Pathology Research International
knockout mice showed enhanced DEN-induced ROS accu-
mulation,JNKactivation,liverdamage,andsubsequenthep-
atocyte proliferation, which resulted in enhanced carcino-
genesis [21]. In addition, hepatocyte-speciﬁc p38α ablation
leads to enhanced IL-1α release from necrotic hepatocytes.
IL-1α can activate Kupﬀer cells, and activated Kupﬀer cells
produce various cytokines, such as TNFα, IL-6, and hepato-
cyte growth factor, which promote proliferation of residual
hepatocytes (Figure 3). The activation of p38 and NF-κBi n
Kupﬀer cells plays an important role in this process because
mice with p38α or IKKβ knockout in both hepatocytes
and myeloid cells, including Kupﬀer cells, showed markedly
reduced hepatic expression of these cytokines after DEN
challenge,resultinginreducedfutureHCCdevelopment[21,
78]. Thus, p38α and NF-κB in the hepatocytes act as tumor
suppressors by conferring protection against DEN-induced
cell death, whereas p38α and NF-κB in the Kupﬀer cells
act as tumor promoters by enhancing cytokine production.
Another study using hepatocyte-speciﬁc p38α knockout
mice indicated its role in tumor suppression by focusing
on the antiproliferative function at the advanced stage [19].
Ablation of p38α in the hepatocytes results in upregulation
of the JNK/c-Jun pathway, which plays an important role in
the increased proliferation of tumor cells.
In human samples, the activity of the MKK6-p38 path-
way is decreased in HCC tissues compared to adjacent non-
tumor tissues [122]. In particular, its activity is signiﬁcantly
lower in larger HCC tissues, suggesting that the p38 pathway
may play an antiproliferative role in human HCC.
4.4. Role of MAP3Ks in Hepatocarcinogenesis. The evidence
presented to date suggests that JNK generally acts as a tumor
promoter and p38 generally acts as a tumor suppressor
in hepatocarcinogenesis. However, as JNK and p38 have
complex functions and modulate a wide range of cellular
eﬀect, some studies showed dual roles of these molecules in
hepatocarcinogenesis. Furthermore, cross talk among JNK
and p38, and molecules involved in other signaling pathways
such as NF-κB, further complicate their roles. Several recent
studieshaveuncoveredtherolesofMAP3Ksintheregulation
of stress-activated MAPK signaling in hepatocarcinogenesis.
One player is TAK1, which can activate NF-κBa sw e l l
as JNK and p38 in response to the signaling of Toll-
like receptors, IL-1 receptor, TNF receptor, and TGF-β
receptor. As mentioned above, hepatocyte-speciﬁc TAK1
knockout mice show spontaneous hepatocyte death, which
is partially mediated by endogenous TNFα [82, 83]. This
spontaneous cell death subsequently causes compensatory
hepatocyte proliferation, inﬂammation, and ﬁbrosis. Fur-
thermore, about 80%–90% of these mice spontaneously
develop HCC at 9 months of age. These phenomena, which
resembled the phenotype observed in hepatocyte-speciﬁc
NF-κB knockout mice, are considered to occur through
attenuated NF-κB activation and elevated JNK activation.
The p38 pathway, however, seems not to be involved in
this phenotype. Thus, TAK1 in the hepatocytes acts as a
tumor suppressor mainly by regulating activation of the
NF-κB pathway. Unexpectedly, crossing hepatocyte-speciﬁc
TAK1 knockout mice with NEMO knockout mice attenuates
JNK activation and prevents hepatocyte death and the
development of HCC, suggesting that NEMO has a tumor-
promoting function in the setting of TAK1 deletion [83].
Furthermore, this function of NEMO is considered to be
independent of NF-κB.
Another player is ASK1, which selectively activates JNK
and p38 signaling in response to a variety of stimuli, includ-
ing ROS and cytokines [123] .T h er o l eo fA S K 1i nh e p a t o -
carcinogenesis has been investigated using the DEN-induced
HCC model [54]. The number of tumors in ASK1−/− mice
is three times higher than that in wild-type controls, and
cancer cell apoptosis is signiﬁcantly suppressed in ASK1−/−
HCC. JNK activation and hyperphosphorylation of BimEL,
which are required for death receptor-mediated apoptosis,
including TNF-R and Fas, are attenuated in ASK1−/− HCC
but not in non-tumor tissues, suggesting escape from the
antitumor immune response. In contrast, tumor-promoting
functions of JNK, such as cell proliferation and neovascu-
larization, are preserved in ASK1−/− mice. Therefore, ASK1
is considered to play a major part in the tumor-suppressing
role of JNK in hepatocarcinogenesis. In addition, activation
of the p38 pathway is also attenuated in ASK1−/− mice, and
DNA damage-induced p21 upregulation via the p38 pathway
is inhibited. Thus, ASK1 controls the tumor-suppressing
function of stress-activated MAPK signaling through induc-
tion of apoptosis and the DNA damage response, and acts
as a tumor suppressor in hepatocarcinogenesis (Figure 4).
Furthermore, another recent study indicated that ASK1 and
Bim are also required for sorafenib-induced apoptosis in
HCC cells [124]. Therefore, ASK1 may play important roles
in not only hepatocarcinogenesis but also in the therapeutic
eﬀects of anticancer drugs.
In some cases, MAP3K may be a better therapeutic target
than MAPK. To date, more than ten molecules have been
identiﬁed as MAP3K in stress-activated MAPK signaling,
which is much more than the number of the downstream
MAPK (Figure 1)[ 125]. This fact indicates that the MAP3Ks
are activated by various stimuli, and function as signaling
hubs, integrating these signals into a unique pattern of
MAPK activation, and eventually leading to a speciﬁc func-
tion of MAPK to the stimulus. Thus, blocking MAP3K may
be able to inhibit speciﬁc function of MAPK. In addition,
inhibition of JNK or p38 causes compensatory activation of
another stress-activated MAPK, whereas inhibition of some
MAP3Ks such as ASK1 does not cause such compensation,
which may be advantageous in the clinical settings as
discussed in the next section. However, which MAP3K is
importantingrowthfactor-mediatedJNKactivationinHCC
remains unclear, especially in vivo, although MEKK1 and
MLK3 have been reported to be involved in this role of JNK
in non-HCC cells such as colon cancer [126, 127]. Therefore,
further understanding of the regulatory system of stress-
activated MAPK signaling by MAP3Ks is important.
5.FuturePerspectives
These recent studies have gradually clariﬁed the roles and
regulation systems of stress-activated MAPK in hepato-
carcinogenesis, but some issues remain to be elucidated.Pathology Research International 9
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Figure 4: Roles of MAP3Ks in controlling the function of stress-
activated MAPK and NF-κB in hepatocarcinogenesis. TAK1 can
activate NF-κB and JNK, but TAK1 mainly regulates NF-κB
activation and acts as a tumor suppressor in hepatocarcinogenesis.
ASK1 controls the tumor-suppressing function of JNK and p38
through apoptosis induction and DNA damage response, and thus
acts as a tumor suppressor. MEKK1 and MLK3 may be involved
in JNK-mediated tumor cell proliferation in hepatocarcinogenesis,
but no supporting in vivo evidence exists to support this contention
at present. Furthermore, the roles of these molecules may diﬀer
according to the disease model and timing.
One issue is that the role of these molecules may change
according to the disease model. A good example is NF-κB.
As mentioned above, DEN-induced HCC is increased in
hepatocyte-speciﬁc IKKβ knockout mice and spontaneous
HCC development is seen in hepatocyte-speciﬁc NEMO
knockout mice, suggesting a role of NF-κBa sat u m o rs u p -
pressor [69, 78]. However, experiments crossing transgenic
mice expressing a nondegradable IκBα mutant with MDR2
knockout mice, which show chronic inﬂammation in the
portal area and subsequent cancer development, indicated
a tumor-promoting role of NF-κB[ 128]. These results
indicate the dual roles of NF-κB in hepatocarcinogenesis
depending on the disease model. Thus, more appropriate
models mimicking human chronic hepatitis and hepato-
carcinogenesis are required. In this sense, TAK1 knockout
mice may be a promising candidate because TAK1-deﬁcient
HCC develops in the context of chronic inﬂammation and
ﬁbrosis, as commonly found in human HCC [82, 83].
Furthermore, the time manipulation is also an important
problem. For example, studies in TAK1 knockout and ASK1
knockout mice conﬁrmed that too much apoptosis in the
chronicinﬂammatoryphasefacilitateshepatocarcinogenesis,
whereas too little apoptosis in already initiated cells also
aggravates cancer progression, suggesting that the apoptotic
function plays dual roles in a stage-dependent manner
[54, 82, 83]. Therefore, therapeutic targets may need to be
redeﬁned according to the carcinogenic stage.
The critical role of stress-activated MAPK signaling in
hepatocarcinogenesis prompts their introduction (especially
JNK1) into the clinical settings as therapeutic targets. Several
inhibitorstargetingJNKorp38haveenteredclinicaltrialsfor
other diseases. In particular, p38 inhibitors for inﬂammatory
diseases, such as rheumatoid arthritis and inﬂammatory
bowel disease, have been studied extensively [129, 130].
However, few have progressed beyond phase I clinical trials
and none have yet appeared in clinical settings. One reason
for this is the occurrence of side eﬀects, such as liver toxicity.
Although whether these are due to target inhibition or to
the eﬀects of the drugs on additional targets is unclear,
cross talk among signaling pathways is considered to be one
explanation because p38 inhibition induces compensatory
JNK activation. Therefore, alternative strategies, such as the
targeting of particular MAPK isoforms, including JNK1,
upstream regulators, including MAP3K, and downstream
eﬀectors, including Bcl-2 family members, will be more
beneﬁcial than targeting the whole pathway. Note that
the roles of these molecules diﬀer among cell types, such
as hepatocytes and myeloid cells, including Kupﬀer cells.
Therefore, one must take into account its total function in
disease progression. Furthermore, combination therapies are
likely to be more important in the future. Hence, further
understanding of these pathways will help to develop novel
treatment strategies for advanced HCC or prevention of
HCC development.
6. Conclusion
Recent studies have indicated that MAPK signaling pathways
play key roles and have potential as therapeutic targets in
liver injury and hepatocarcinogenesis. Among them, JNK
signaling is a promising therapeutic target. However, these
pathways have a wide range of functions and show complex
cross talk. In addition, their roles diﬀer between cell types
and disease processes. Our ﬁnal goal is to establish them
as new diagnostic markers and targets for therapies or
preventionofliverdiseases.Infact,recentreportshowedthat
activation of JNK in noncancerous liver tissue predicted a
high risk of HCC recurrence after surgical resection, suggest-
ingthattesting JNKactivationin thelivermight beusefulfor
the risk assessment of HCC occurrence or recurrence [131].
Thus, further understanding of these very important and
complicatedpathways,includingsurroundingmodulators,is
essential for application in clinical settings.
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